Date: Wednesday, 13 April 2022
Time: 12:30pm - 1:15pm
Register for this Zoom Webinar
1. Breaking the barrier: Using focused ultrasound for the development of targeted therapies for brain tumours.
Dr Ekaterina (Caty) Salimova, Monash Biomedical Imaging
Glioblastoma multiforme (GBM) - brain cancer - is aggressive and difficult to treat as systemic therapies are hindered by the blood-brain barrier (BBB). Focused ultrasound (FUS) - a non-invasive technique that can induce targeted temporary disruption of the BBB – is a promising tool to improve GBM treatments.
In this webinar, Dr Ekaterina Salimova will discuss the MRI-guided FUS modality at MBI and her research to develop novel targeted therapies for brain tumours.
2. Disposition of the Kv1.3 inhibitory peptide HsTX1[R14A], a novel attenuator of neuroinflammation
Ms Sanjeevini Babu Reddiar, Monash Institute of Pharmaceutical Sciences
The voltage-gated potassium channel (Kv1.3) in microglia regulates membrane potential and pro-inflammatory functions, and non-selective blockade of Kv1.3 has shown anti-inflammatory and disease improvement in animal models of Alzheimer’s and Parkinson’s diseases. Therefore, specific inhibitors of pro-inflammatory microglial processes with CNS bioavailability are urgently needed, as disease-modifying treatments for neurodegenerative disorders are lacking.
In this webinar, PhD candidate Ms Sanju Reddiar will discuss the synthesis and biodistribution of a Kv1.3-inhibitory peptide using a [64Cu]Cu-DOTA labelled conjugate.
Enquiries: T: +61 (3) 9905 0100 | E: enquiries.mbi@monash.edu
